Business

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today

articlePasithea Therapeutics Corp.December 28, 20233/company/pasithea-therapeutics-corp/news/pasithea-therapeutics-announces-adjournment-of-reconvened-meeting-of-stockholders-to-december-29-2023
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

About this update from Pasithea Therapeutics Corp.

[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif. and MIAMI, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (NASDAQ: KTTA) today announced that its meeting of stockholders, which had been partially adjourned on December 19, 2023, was reconvened on December 28, 2023 (the “Meeting”) and then was further adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the charter amendment proposals included as Proposals 4, 5(A), 5(B) and 5(C) (the “Adjourned Proposals”) in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (“SEC”) on October 26, 2023 (the “Proxy Statement”). The adjourned Meeting will reconvene on December 29, 2023 at 11:00 a.m. Eastern Time at www.virtualshareholdermeeting.com/KTTA2023. The original record date of October 12, 2023 remains the same for the adjourned Meeting. Stockholders of record may attend the virtual webcast meeting by logging in through the same method as set forth in the Proxy Statement. During this adjournment, the Company will continue to solicit votes from its stockholders in favor of the Adjourned Proposals in the Proxy Statement. The Company’s board of directors believes approval of the Adjourned Proposals are advisable and in the best interests of the Company and its stockholders for the reasons described in the Proxy Statement. Voting remains open only as to the Adjourned Proposals, and these are the only proposals that will be voted upon at the adjourned Meeting. Voting for all meeting proposals other than the Adjourned Proposals was previously closed, and those proposals were previously approved by stockholders, as reported in the Company’s Form 8-K filed with the SEC on December 19, 2023. Stockholders who have already voted their shares on the Adjourned Proposals do not need to vote again. Proxies previously submitted will be voted at the adjourned Meeting, and stockholders who have previously submitted a proxy or otherwise voted on the Adjourned Proposals need not take any action. Pasithea encourages all stockholders as of the record date on October 12, 2023 who have not yet voted on the Adjourned Proposals to do so promptly. Stockholders wishing to vote on the Adjourned Proposals should contact the Company’s proxy solicitor, Alliance Advisors, toll free at (888) 490-5...

More updates from Pasithea Therapeutics Corp.